###begin article-title 0
Primate Lentiviral Vpx Commandeers DDB1 to Counteract a Macrophage Restriction
###end article-title 0
###begin p 1
Conceived and designed the experiments: N. Sharova Y. Wu X. Zhu R. Stranska R. Kaushik M. Sharkey M. Stevenson. Performed the experiments: N. Sharova Y. Wu X. Zhu R. Stranska M. Sharkey. Analyzed the data: N. Sharova Y. Wu X. Zhu R. Stranska M. Stevenson. Wrote the paper: N. Sharova Y. Wu X. Zhu R. Stranska M. Stevenson.
###end p 1
###begin p 2
###xml 272 274 272 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 691 699 691 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in trans</italic>
###xml 263 268 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 553 556 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 577 580 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 647 652 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 728 733 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 738 741 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 901 906 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 911 914 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 948 953 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Primate lentiviruses encode four "accessory proteins" including Vif, Vpu, Nef, and Vpr/Vpx. Vif and Vpu counteract the antiviral effects of cellular restrictions to early and late steps in the viral replication cycle. We present evidence that the Vpx proteins of HIV-2/SIVSM promote virus infection by antagonizing an antiviral restriction in macrophages. Fusion of macrophages in which Vpx was essential for virus infection, with COS cells in which Vpx was dispensable for virus infection, generated heterokaryons that supported infection by wild-type SIV but not Vpx-deleted SIV. The restriction potently antagonized infection of macrophages by HIV-1, and expression of Vpx in macrophages in trans overcame the restriction to HIV-1 and SIV infection. Vpx was ubiquitylated and both ubiquitylation and the proteasome regulated the activity of Vpx. The ability of Vpx to counteract the restriction to HIV-1 and SIV infection was dependent upon the HIV-1 Vpr interacting protein, damaged DNA binding protein 1 (DDB1), and DDB1 partially substituted for Vpx when fused to Vpr. Our results indicate that macrophage harbor a potent antiviral restriction and that primate lentiviruses have evolved Vpx to counteract this restriction.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 58 61 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 325 328 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 329 332 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 578 581 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 582 585 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 684 687 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 688 691 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 819 822 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 827 830 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1019 1022 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Defense against infection by the primate lentiviruses HIV/SIV is mediated primarily by antibodies that can neutralize the virus and by cytotoxic cells that can recognize and kill other virus-infected cells. However, in the past several years, research has revealed the existence of an additional line of host defense against HIV/SIV. It is now apparent that cells contain factors (also known as cellular restrictions) that potently inhibit virus infection. This has forced primate lentiviruses to evolve a strategy to counteract these cellular restriction factors. For example, HIV/SIV encode an accessory protein called Vif, whose function is to neutralize a cellular restriction to HIV/SIV infection. Our study provides evidence for a novel restriction that is expressed by macrophages and which potently antagonizes HIV and SIV infection. We describe how the virus protects itself from this cellular restriction. The goal is to harness this cellular restriction as the basis for a novel therapeutic strategy against HIV infection.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 168 171 168 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Emerman1">[1]</xref>
###xml 345 348 345 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Sheehy1">[2]</xref>
###xml 446 449 446 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Neil1">[3]</xref>
###xml 648 650 648 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 654 657 654 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAC</sub>
###xml 796 799 796 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vpr</italic>
###xml 841 844 841 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Fletcher1">[4]</xref>
###xml 943 946 943 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Lu1">[5]</xref>
###xml 947 950 947 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Kappes1">[7]</xref>
###xml 1056 1063 1056 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1354 1357 1354 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-He1">[8]</xref>
###xml 1358 1362 1358 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Rogel1">[11]</xref>
###xml 1407 1411 1407 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Bouhamdan1">[12]</xref>
###xml 1531 1535 1531 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Balliet1">[13]</xref>
###xml 1536 1540 1536 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Goujon1">[17]</xref>
###xml 1633 1635 1633 1635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 1653 1655 1653 1655 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 1818 1821 1818 1821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Fletcher1">[4]</xref>
###xml 1822 1826 1822 1826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Sleigh1">[18]</xref>
###xml 1968 1970 1968 1970 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 2097 2100 2097 2100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Fletcher1">[4]</xref>
###xml 2101 2105 2101 2105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Sleigh1">[18]</xref>
###xml 458 461 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 466 469 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 639 644 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 775 795 <span type="species:ncbi:9534">African green monkey</span>
###xml 1232 1237 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1262 1267 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1548 1553 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1624 1629 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 1644 1649 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 1893 1896 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
The genomes of primate and non-primate lentiviruses encode "accessory" proteins from short open reading frames which are absent from the genomes of simple retroviruses [1]. The function of two of the accessory proteins, the Vif and Vpu proteins, have been defined: Vif antagonizes the antiviral activity of cellular Apobec 3 cytidine deaminases [2] and Vpu antagonizes the activity of tetherin to promote release of virions from the cell surface [3]. In all HIV and SIV lineages, the central viral region (overlapping Vif and Tat open reading frames) encodes at least one gene which is usually termed viral protein R (Vpr). Members of the HIV-2/SIVSM/SIVMAC lineage contain an additional gene in this region termed viral protein X (Vpx) which was originally derived from the African green monkey vpr gene by an ancestral recombination event [4]. Both Vpr and Vpx proteins are packaged into virions through association with the Gag polyprotein [5]-[7] and this points to an early role for these proteins in the virus life cycle (i.e., at a point proceeding de novo production of viral proteins). Most of the information regarding the roles of Vpr and Vpx proteins in primate lentivirus replication has been derived from studies with HIV-1 Vpr. The Vpr protein of HIV-1 has been shown to promote the accumulation of cells in the G2 stage of the cell cycle [8]-[11] and to associate with the DNA repair enzyme [12]. In addition, Vpr has been shown to promote the infection of terminally differentiated macrophages and dendritic cells [13]-[17]. These HIV-1 Vpr-ascribed activities segregate between the Vpx and Vpr proteins of HIV-2/SIVSM: Vpr of HIV-2/SIVSM induces cell cycle arrest and associates with UDG but is dispensable for macrophage infection while Vpx neither induces cell cycle arrest nor associates with UDG [4],[18]. However, Vpx is essential for infection of simian macrophages by SIV in vitro and following infection of simian macrophages by Vpx minus SIVSM, late cDNA product are reduced while 2-LTR cDNAs, which are formed only after completion of reverse transcription, are absent [4],[18]. Whether any of these activities relate to the functional role of Vpr/Vpx proteins in primate lentivirus replication, is unclear. In order to understand the functions of the Vpr/Vpx proteins in macrophage infection, we have focused on Vpx because of its profound impact on macrophage infection. In addition, its effect can be studied independently of other Vpr/Vpx-assigned activities including UDG association and cell cycle arrest.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
Vpx is required for infection of heterokaryons between permissive and non-permissive cells
###end title 8
###begin p 9
###xml 48 50 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 155 158 155 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Fletcher1">[4]</xref>
###xml 205 207 205 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Dewhurst1">[19]</xref>
###xml 39 44 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
We previously demonstrated that Vpx of HIV-2/SIVSM was essential for early events in macrophage infection yet dispensable for infection of CD4 lymphocytes [4]. We studied Vpx function in the context of SIVSM PB j which represents a primary isolate [19]. To increase particle infectivity and facilitate analysis of early events in the viral life cycle, viruses were pseudotyped with VSV-G envelope proteins. Although VSV pseudotyping has been shown to alleviate the defects exhibited by other accessory gene mutants such as Nef, pseudotyping did not alleviate the infectivity defect of Vpx-deleted viruses in macrophages. In order to gauge infection of primary macrophages under single cycle conditions, we quantitated viral cDNAs (mainly 2-LTR cDNA) by real time PCR. In this study, where we were dealing with a restriction and the viral target of the restriction was unknown, it seemed prudent to conduct experiments predominantly with viruses intact for all open reading frames as opposed to recombinant indicator viruses.
###end p 9
###begin p 10
###xml 69 71 69 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 90 99 90 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 90 99 90 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1A</bold></xref>
###xml 373 382 373 382 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 373 382 373 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1A</bold></xref>
###xml 502 511 502 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 502 511 502 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1A</bold></xref>
###xml 907 916 899 908 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S1</bold>
###xml 907 916 899 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000057.s001"><bold>Figure S1</bold></xref>
###xml 938 941 930 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Fletcher1">[4]</xref>
###xml 1410 1419 1402 1411 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 1410 1419 1402 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1A</bold></xref>
###xml 1547 1556 1539 1548 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 1547 1556 1539 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1A</bold></xref>
###xml 1664 1673 1656 1665 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 1664 1673 1656 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1A</bold></xref>
###xml 1674 1675 1666 1667 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
###xml 2371 2375 2363 2367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Simon1">[20]</xref>
###xml 2376 2380 2368 2372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Madani1">[21]</xref>
###xml 2508 2510 2500 2502 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 2695 2704 2683 2692 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 2695 2704 2683 2692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1B</bold></xref>
###xml 2942 2951 2930 2939 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 2942 2951 2930 2939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1B</bold></xref>
###xml 3160 3169 3148 3157 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 3160 3169 3148 3157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1B</bold></xref>
###xml 3283 3292 3267 3276 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 3283 3292 3267 3276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1B</bold></xref>
###xml 60 65 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 314 317 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 325 328 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 477 480 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 972 975 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1236 1241 <span type="species:ncbi:9606">human</span>
###xml 1259 1262 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1381 1384 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1453 1456 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 2598 2601 <span type="species:ncbi:11176?0.9656862745098039">NDV</span>
###xml 2899 2902 <span type="species:ncbi:11176?0.9656862745098039">NDV</span>
###xml 3155 3158 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
The profound requirement for Vpx in macrophage infection by HIV-2/SIVSM is illustrated in Figure 1A. 2-LTR cDNA is formed only after completion of viral reverse transcription and translocation of viral cDNA to the nucleus where circularization occurs. Levels of 2-LTR cDNA in macrophages infected with a wild-type SIV and an SIV variant lacking Vpr were indistinguishable (Figure 1A). In contrast, viral 2-LTR cDNA was reduced at least 100 fold in macrophages infected with an SIV variant lacking Vpx (Figure 1A). In COS cells and in HeLa cells, viral cDNA synthesis with wild type and Vpr-deleted or Vpx-deleted viruses were similar. Although 2-LTR cDNA was not detected in macrophages infected with SIVDelta Vpx, late viral cDNAs were evident but at a reduced level. Late cDNAs were reduced 15 fold and 2 fold at 24 and 48 h respectively in SIVDelta Vpx as compared to wild type infection of macrophages (Figure S1). Our original study [4] on the requirement for Vpx in SIV infection of monkey macrophages reported a predominant defect in 2-LTR circle formation and an approximately 3 fold defect in late cDNA synthesis using non quantitative PCR. This is consistent with the defect observed in this study which involves infection of human macrophages with SIV. The greater than 100 fold defect in 2-LTR cDNA formation was recapitulated in macrophage infections with Vpx deleted SIV variants expressing GFP (Figure 1A). This analysis revealed that an SIV variant lacking Vpx was at least 100 fold less infectious than the wild type counterpart (Figure 1A). Although Vpx was necessary for macrophage infection, it was dispensable for infection of COS/HeLa cells (Figure 1A). This suggested the existence of cellular activities, differentially expressed between macrophages and COS or HeLa cells, which impact primate lentivirus infection. One possibility was that COS and HeLa cells contain a cellular activity which promotes virus infection but in macrophages, this activity must be activated by the Vpx protein. An alternative possibility was that macrophages contain a cellular restriction to infection which is counteracted by the Vpx protein and this cellular restriction is not expressed in COS or HeLa cells. To distinguish between these two possibilities, we used a strategy previously adopted to characterize the mechanism by which Vif promotes viral infection [20],[21]. Heterokaryons were generated between macrophages and COS cells and the susceptibility of the heterokaryons to infection by SIVWT and SIVDelta Vpx was compared. When the fusogenic proteins of Newcastle Disease Virus (NDV) were expressed in COS cells, these cells readily underwent fusion with primary macrophages (Figure 1B). Macrophage/COS heterokaryons (double staining cells) were isolated by fluorescence-activated cell sorting (FACS). Double staining cells were not observed when normal COS cells (not expressing NDV proteins) were mixed with macrophages (Figure 1B). As an additional control, macrophage homokaryons were produced using polyethylene glycol (PEG). Both macrophage/COS heterokaryons as well as COS and macrophage homokaryons were infectible by wild type SIV (Figure 1B). In contrast, macrophage homokaryons and macrophage/COS heterokaryons were resistant to SIVDelta Vpx infection (Figure 1B). Since fusion with COS cells did not relieve the block to macrophage infection by SIVDelta Vpx, this indicated that macrophages harbor an antiviral restriction which is counteracted by the Vpx protein and this restriction is absent from COS and HeLa cells.
###end p 10
###begin title 11
Vpx antagonizes an antiviral restriction in macrophages.
###end title 11
###begin p 12
###xml 156 158 148 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 374 375 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 379 380 371 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 386 387 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 404 406 396 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 417 418 409 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 434 442 426 430 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Vpx</sub>
###xml 1399 1401 1387 1389 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 1409 1417 1397 1401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpx</sub>
###xml 323 326 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 591 594 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1050 1053 <span type="species:ncbi:11176?0.9656862745098039">NDV</span>
###xml 1087 1090 <span type="species:ncbi:11176?0.9656862745098039">NDV</span>
(A) Differential susceptibility of macrophages and cell lines to infection by wild type and Vpx-deleted (DeltaVpx) or Vpr-deleted (DeltaVpr) variants of SIVSM. Virus infection was gauged from the levels of viral 2-LTR cDNA at 24 and 48 h post infection. Right panels, comparison of infectivity of wild type and Vpx deleted SIV GFP variants. Macrophages were infected with 107, 106 or 105 RT unites of SIVWT -GFP or 107 RT units of SIVDeltaVpx GFP. Macrophages were visualized 48 h post infection by phase and fluorescence microscopy (B) Differential infectivity of wild type and Vpx-deleted SIV variants for macrophage-COS heterokaryons. Heterokaryons were formed between primary macrophages and between COS cells expressing fusogenic HN and F proteins of Newcastle Disease Virus. To visualize heterokaryons by fluorescence microscopy, COS cells were stained with DiO (green) and macrophages were stained with DiI (red) (magnification x320; left panel). FACS analysis of macrophage-COS heterokaryons (middle panel). COS cells were cotransfected with NDV HN and F expression vectors (COS-NDV) or with empty, control vectors (COS). COS cells were stained with CellTracker Green CMFDA and macrophages were stained with CellTracker Blue CMAC. Double-stained cells were sorted as indicated by the gate. Susceptibility of macrophage/COS heterokaryons and COS and macrophage homokaryons to infection by SIVWT and SIVDeltavpx virus variants (right panel). Infection was gauged from levels of late cDNAs and 2-LTR circle cDNAs (error bars are s.d. of 6 replicate samples from two independent experiments).
###end p 12
###begin title 13
###xml 29 37 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in trans</italic>
Vpx counters the restriction in trans
###end title 13
###begin p 14
###xml 140 147 140 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 269 277 269 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in trans</italic>
###xml 454 455 448 449 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 455 463 449 457 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 455 463 449 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g002"><bold>Figure 2</bold></xref>
###xml 463 464 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 680 681 664 665 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 681 689 665 673 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 681 689 665 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g002"><bold>Figure 2</bold></xref>
###xml 689 690 673 674 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 903 904 875 876 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 904 912 876 884 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 904 912 876 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g002"><bold>Figure 2</bold></xref>
###xml 912 913 884 885 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 1055 1056 1023 1024 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1056 1064 1024 1032 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 1056 1064 1024 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g002"><bold>Figure 2</bold></xref>
###xml 1064 1065 1032 1033 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 1181 1182 1145 1146 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1182 1190 1146 1154 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 1182 1190 1146 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g002"><bold>Figure 2</bold></xref>
###xml 1190 1191 1154 1155 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 1226 1228 1190 1192 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 1325 1333 1289 1297 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 1325 1333 1289 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g002"><bold>Figure 2</bold></xref>
###xml 1430 1438 1394 1402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in trans</italic>
###xml 401 404 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 595 598 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1127 1130 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1297 1300 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Vpx and Vpr are virion proteins and would thus be predicted to exert their function in the target cell shortly after infection and prior to de novo synthesis of viral proteins. Therefore, we examined whether Vpx delivered to macrophages would alleviate the restriction in trans to subsequent infection by a Vpx deleted virus. Macrophages were first infected (1degrees infection) with envelope deleted SIV variants harboring intact or defective Vpx genes (Figure 2). After an additional 8 or 16 hours, macrophages were subsequently super-infected (2degrees infection) with wild type or Delta Vpx SIV variants. Viral cDNA products were amplified using envelope-specific PCR primers (Figure 2). cDNA products amplified by these envelope specific primers were derived specifically from the secondary (2degrees) infection since viruses used in the primary infection (1degrees) lacked an intact envelope gene (Figure 2). Infection of macrophages harboring a wild type Vpx gene alleviated the block to subsequent SIVDelta Vpx super-infection 8 or 16 hours later (Figure 2). In contrast, macrophages initially infected with a DeltaVpx SIV remained refractory to subsequent super-infection (Figure 2). Infection of macrophages with SIVWT also removed the restriction to subsequent infection by a Vpx minus SIV variant expressing GFP (Figure 2). This provided evidence that Vpx, delivered to the target cell, can counteract the restriction in trans.
###end p 14
###begin title 15
###xml 35 37 35 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 94 102 94 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpx</sub>
Vpx delivered to macrophages by SIVWT infection removes a block to subsequent infection by SIVDeltavpx.
###end title 15
###begin p 16
###xml 268 270 256 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 277 285 265 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpx</sub>
###xml 489 491 473 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 498 506 482 486 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpx</sub>
###xml 537 539 511 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 546 554 520 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpx</sub>
###xml 83 86 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
(A) Macrophages were initially infected (1degrees infection) with envelope deleted SIV variants harboring intact or defective Vpx genes. The nature of the envelope deletion is shown in the lower panel. Those cells were then super-infected (2degrees infection) with SIVWT or SIVDeltavpx variants harboring intact envelope genes. cDNA products resulting from the super infection were then specifically amplified using envelope-specific primers. (B) Similar experiment was performed using SIVWT or SIVDeltavpx for 1degrees infection and SIVWT or SIVDeltavpx GFP variants for 2degrees infection. Number of GFP-positive cells was determined 24 hr post 2degrees infection (error bars are s.d., n = 3).
###end p 16
###begin title 17
Role of ubiquitylation in biological activity of Vpx
###end title 17
###begin p 18
###xml 138 142 138 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Cullen1">[22]</xref>
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Harris1">[23]</xref>
###xml 425 434 425 434 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 425 434 425 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3A</bold></xref>
###xml 434 447 434 447 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, lower panel</bold>
###xml 722 731 722 731 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 722 731 722 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3A</bold></xref>
###xml 1060 1069 1060 1069 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 1060 1069 1060 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3A</bold></xref>
###xml 1069 1082 1069 1082 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, right panel</bold>
###xml 1228 1237 1228 1237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 1228 1237 1228 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3A</bold></xref>
###xml 1374 1376 1374 1376 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M4</sub>
###xml 1476 1480 1476 1480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Wang1">[24]</xref>
###xml 1481 1485 1481 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Cadwell1">[25]</xref>
###xml 1628 1636 1628 1632 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Vpx</sub>
###xml 1753 1762 1749 1758 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 1753 1762 1749 1758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3B</bold></xref>
###xml 1840 1849 1836 1845 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 1840 1849 1836 1845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3B</bold></xref>
###xml 1896 1898 1892 1894 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M4</sub>
###xml 2006 2009 2002 2005 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NM2</sub>
###xml 2117 2126 2113 2122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 2117 2126 2113 2122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3B</bold></xref>
###xml 2527 2529 2523 2525 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M4</sub>
###xml 2693 2702 2689 2698 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3C</bold>
###xml 2693 2702 2689 2698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3C</bold></xref>
###xml 2940 2943 2936 2939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Lu1">[5]</xref>
###xml 2944 2947 2940 2943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Cohen1">[6]</xref>
###xml 1536 1539 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Primate lentiviruses have evolved the accessory protein Vif to counteract the antiviral activity of cellular Apobec 3 cytidine deaminases [22]. Vif achieves this by promoting ubiquitylation and proteasomal destruction of Apobec 3 proteins [23]. To evaluate a possible role for the ubiquitin-proteasome system in the activity of Vpx, we first evaluated whether Vpx itself was ubiquitylated. HA-tagged Vpx and mutants thereof (Figure 3A, lower panel) were co-expressed in 293T cells with 6-Histidine-myc-tagged ubiquitin. Mono and poly ubiquitylated Vpx proteins were purified on nickel beads and Western blotted. Immunoblotting with an HA antibody revealed the presence of mono and poly ubiquitylated forms of Vpx (Ub-Vpx, Figure 3A). We also examined whether Vpx was ubiquinated by endogenous ubiquitin (as opposed to over expressed and tagged ubiquitin). HA-tagged Vpx was expressed in 293 T cells and cell lysates were directly Western blotted and probed with an HA antibody. This revealed the presence of higher molecular weight ubiquitylated forms of Vpx (Figure 3A, right panel). The extent of Vpx ubiquitylation was reduced to various extents in Vpx mutants containing single or multiple lysine to arginine substitutions (Figure 3A). Despite mutagenesis of all four lysines in Vpx, polyubiquitylated forms of the protein were still evident (compare GFP signal with VpxM4 signal). This suggested an involvement of both lysine and nonlysine residues in Vpx ubiquitylation [24],[25]. The ability of the Vpx lysine mutants to support SIV infection of macrophages was next examined. The various mutants were packaged within SIVDeltaVpx virions and single cycle infection of macrophages was evaluated from synthesis of late viral cDNAs and 2-LTR cDNAs (Figure 3B). The infectivity of the Vpx lysine mutants was impaired to various degrees (Figure 3B). The Vpx mutated lacking all four lysine (VpxM4) exhibited the lowest infectivity for macrophage. However, a mutant lacking the two N-terminal lysines (VpxNM2) appeared to be efficiently ubiquitylated yet this mutant also exhibited a significant infectivity defect (Figure 3B). However, due to technical obstacles in transfection of primary macrophages, we were unable to evaluate the extent of Vpx ubiquitylation of the various lysine mutants in primary macrophages and for this reason, we were unable to directly assess whether the extent of Vpx ubiquitylation was proportional to Vpx biological activity. For subsequent experiments, we focused on the use of Vpx mutant (VpxM4) containing substitutions at all four lysine residues. This mutant was efficiently packaged within virus particles at levels indistinguishable from wild type Vpx (Figure 3C). The packaging of the Vpx lysine mutant in viral particles suggests, at the very least, that this mutant is competent for binding to the p6 domain of the viral Gag polyprotein through which packaging of Vpr and Vpx proteins is mediated [5],[6].
###end p 18
###begin title 19
###xml 62 65 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Role of the proteasome ubiquitylation system in regulation of SIV infectivity by Vpx.
###end title 19
###begin p 20
###xml 232 240 232 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpx</sub>
###xml 366 374 362 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpx</sub>
(A) Identification of ubiquitylated residues in Vpx. Wild type and lysine mutant Vpx proteins (HA tag) were expressed in 293T cells expressing Histidine-tagged ubiquitin. (B) Susceptibility of primary macrophages to infection by SIVDeltavpx packaging either wild type Vpx or lysine substitution mutants of Vpx. Vpx proteins were packaged after co-transfection of SIVDeltavpx proviral DNA with plasmids expressing wild or lysine mutant Vpx proteins or GFP as a control. Virus infection was gauged from quantitation of late viral cDNAs and 2-LTR cDNAs 48 h post infection (error bars are s.d. of 3 replicate measures of a single DNA sample). (C) Packaging of wild type and non-ubiquitylated Vpx proteins in virus particles (upper panel). The presence of Vpx in gradient purified virions was determined by Western blotting with an HA antibody (lower panel).
###end p 20
###begin title 21
Vpx activity requires a functional proteasome
###end title 21
###begin p 22
###xml 442 450 442 450 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 442 450 442 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g004"><bold>Figure 4</bold></xref>
###xml 543 551 543 551 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 543 551 543 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g004"><bold>Figure 4</bold></xref>
###xml 691 700 691 700 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S2</bold>
###xml 691 700 691 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000057.s002"><bold>Figure S2</bold></xref>
###xml 825 833 825 833 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 835 846 835 846 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</bold>
###xml 825 846 825 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g004"><bold>Figure 4</bold>, <bold>right panel</bold></xref>
###xml 1542 1546 1542 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Goujon1">[17]</xref>
###xml 56 59 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 216 219 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 335 338 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 412 415 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 515 518 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 590 595 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 740 745 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1182 1185 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1190 1195 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
We next examined whether the ability of Vpx to regulate SIV infection of macrophages required proteasome function. Macrophages were treated with three different proteasome inhibitors and then infected with wild type SIV and 2-LTR cDNA was quantitated 24 and 48 hours after infection. Lactacystin had a modest yet significant effect on SIV infection and ALLN and proteasome inhibitor 1 (Prot.1) markedly impaired SIV infection of macrophages (Figure 4). In contrast, neither ALLN nor proteasome inhibitor 1 affected SIV infection of COS cells (Figure 4). Identical results were obtained for HIV-2 in that the proteasome inhibitors compromised macrophage infection but not COS cell infection (Figure S2). In contrast, macrophage infection by HIV-1 (which does not contain Vpx) was not compromised by the proteasome inhibitors (Figure 4, right panel). Since proteasome disruption only impacted virus infection of cells in which Vpx was required for infection, this argued that proteasome inhibition specifically impaired Vpx function rather than impacting virus infection through off-target effects. The proteasome inhibitor lactacystin exerted a more modest but significant effect on SIV and HIV-2 infection of macrophages when compared to the other proteasome inhibitors. However, we were unable to test lactacystin in primary macrophages at higher concentrations because of toxicity. Similar toxic effects of proteasome inhibitors in primary dendritic cells have also limited complete suppression of proteasome function using such inhibitors [17]. Collectively, these experiments indicate the presence of a potent antiviral restriction in macrophages that is counteracted by the Vpx protein and that the proteasome/ubiquitin system is required for the ability of Vpx to counteract this restriction.
###end p 22
###begin title 23
###xml 51 53 51 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 58 63 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Differential impact of proteasome inhibition on SIVWT and HIV-1 infection of macrophages.
###end title 23
###begin p 24
###xml 48 51 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effects of 3 different proteasome inhibitors on SIV infection of macrophages and COS cells and HIV-1 infection of macrophages are indicated. Viral infection (2-LTR cDNA) was gauged at 24 and 48 h post infection (error bars and s.d. of 3 replicate measures of a single DNA sample).
###end p 24
###begin title 25
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The macrophage restriction is active against HIV-1
###end title 25
###begin p 26
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 190 198 190 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in trans</italic>
###xml 451 460 447 456 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 451 460 447 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g005"><bold>Figure 5A</bold></xref>
###xml 460 473 456 469 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, lower panel</bold>
###xml 612 621 608 617 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5B</bold>
###xml 612 621 608 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g005"><bold>Figure 5B</bold></xref>
###xml 837 846 829 838 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 837 846 829 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g005"><bold>Figure 5A</bold></xref>
###xml 846 859 838 851 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, upper panel</bold>
###xml 1289 1291 1277 1279 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M4</sub>
###xml 1366 1375 1354 1363 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5C</bold>
###xml 1366 1375 1354 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g005"><bold>Figure 5C</bold></xref>
###xml 1891 1893 1879 1881 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 2172 2174 2160 2162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 2186 2195 2174 2183 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5D</bold>
###xml 2186 2195 2174 2183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g005"><bold>Figure 5D</bold></xref>
###xml 2314 2323 2298 2307 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5D</bold>
###xml 2314 2323 2298 2307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g005"><bold>Figure 5D</bold></xref>
###xml 2619 2621 2603 2605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M4</sub>
###xml 2702 2711 2682 2691 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</bold>
###xml 2702 2711 2682 2691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g006"><bold>Figure 6A</bold></xref>
###xml 2776 2785 2756 2765 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6B</bold>
###xml 2776 2785 2756 2765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g006"><bold>Figure 6B</bold></xref>
###xml 3192 3201 3172 3181 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6C</bold>
###xml 3192 3201 3172 3181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g006"><bold>Figure 6C</bold></xref>
###xml 70 75 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 126 131 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 206 211 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 341 346 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 367 370 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 440 445 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 554 559 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 636 641 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 816 821 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 922 927 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 955 960 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 977 982 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1025 1030 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1351 1356 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1398 1403 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1618 1623 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1765 1770 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1980 1985 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2078 2083 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2282 2287 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2405 2410 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2496 2501 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2568 2571 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 2639 2644 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2678 2681 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2865 2870 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2973 2978 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3083 3088 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We next evaluated whether the antiviral restriction which antagonized HIV-2/SIVSM infection of macrophages was active against HIV-1. We first examined whether the Vpx protein, when packaged in trans within HIV-1 virions, enhanced virus infectivity for primary macrophages. While Vpx had no significant effect on the infectivity of wild type HIV-1, the infectivity of HIV-1Delta Vpr for macrophages was profoundly enhanced by Vpx but not by HIV-1 Vpr (Figure 5A, lower panel). The infectivity enhancement was also apparent in macrophages infected with an HIV-1 variant expressing green fluorescent protein (GFP) (Figure 5B). Thus, while HIV-1 was infectious for macrophages, its ability to infect these cells was markedly enhanced in the presence of Vpx. Vpx had no effect on the infectivity of wild type or DeltaVpr HIV-1 for COS cells (Figure 5A, upper panel). A possible explanation for the ability of Vpx to compliment HIV-1 DeltaVpr but not wild-type HIV-1 is that Vpx and HIV-1 Vpr proteins compete for packaging within HIV-1 virions. An alternative possibility was that these proteins do not compete for packaging into virions but compete for interaction with the restriction after infection has occurred. Western blotting analysis revealed that both wild type and lysine mutant (VpxM4) Vpx proteins were packaged into wild type and Vpr deleted HIV-1 virions (Figure 5C). This suggested that HIV-1 Vpr competed with Vpx in the target cell following infection and this competition precluded the ability of Vpx to activate the restriction. A prediction of this is that delivery of Vpx to this target cell prior to HIV-1 infection should be sufficient to inactivate the restriction and subsequently enhance macrophage infection by both wild type and Vpr deleted HIV-1. To evaluate this, we bypassed the requirement for Vpx packaging by directly introducing Vpx into the target cell by SIVWT infection. The susceptibility of those cells to infection by wild type or Vpr-deleted HIV-1 variants was then examined. In this case, the infectivity of both wild type and vpr deleted HIV-1 variants for macrophages was enhanced when Vpx was first introduced into the cell by SIVWT infection (Figure 5D). In contrast, prior infection with a SIVDelta Vpx variant did not enhance subsequent HIV-1 infection of macrophages (Figure 5D). Therefore, in the absence of competition by packaged Vpr, Vpx greatly enhanced HIV-1 infectivity for macrophages. We next evaluated whether the ability of Vpx to enhance HIV-1 infectivity depended upon its ubiquitylation. As was the case for SIV, a Vpx mutant lacking ubiquitylation sites (VpxM4) did not enhance HIV-1 infectivity when packaged within HIV-1Delta Vpr virions (Figure 6A). This was also apparent in infections using indicator viruses (Figure 6B). In this case, the ability of Vpx to enhance the infectivity of a Vpr deleted HIV-1 variant expressing GFP was compromised by the M4 mutation. In addition, the ability of Vpx to enhance HIV-1 infectivity required proteasome function in that Vpx failed to enhance permissiveness of macrophages to HIV-1 infection in macrophages in which proteasome function was disrupted by ALLN or proteasome inhibitor 1 (Figure 6C).
###end p 26
###begin title 27
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 53 56 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 is sensitive to the macrophage restriction and SIV Vpx but not HIV-1 Vpr antagonizes the restriction.
###end title 27
###begin p 28
###xml 57 59 57 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 68 76 68 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpr</sub>
###xml 424 432 420 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Vpr</sub>
###xml 677 679 669 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 724 726 716 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 736 744 728 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpr</sub>
###xml 4 9 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 18 21 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 52 55 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 63 66 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 419 422 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 632 637 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 719 722 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 731 734 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 836 839 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 978 983 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 997 1002 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) HIV-1 Vpr and SIV Vpx proteins were packaged in HIV-1WT or HIV-1Deltavpr viruses by cotransfection (for controls, viruses were transfected with an empty vector or a GFP-expressing vector). The infectivity of those viruses for COS (upper panel) and macrophages (lower panel) was then determined from levels of viral cDNA (2-LTR circle) at 24 and 48 h post infection. (B) Infection of macrophages with GFP-expressing HIV-1DeltaVpr variants in which Vpx was (+) or was not (-) packaged. GFP positive macrophages (representative fields) were visualized 48 h post infection (C) Packaging of Vpx proteins in wild type and Vpr deleted HIV-1 (D) Vpx delivered to macrophages by SIVWT infection enhances the permissivity to HIV-1WT and HIV-1Deltavpr infection. Macrophages were first infected (1degrees infection) with wild type or DeltaVpx SIV variants, left uninfected (none) or treated with AZT. After 8 h, these cells were super-infected (2degrees infection) with WT or DeltaVpr HIV-1 variants and HIV-1 infection (2-LTR cDNA synthesis) was determined 24 and 48 h later (error bars are s.d. of 3 replicate PCRs of a single DNA sample).
###end p 28
###begin title 29
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Ubiquitylation is required for enhancement of HIV-1 infectivity in macrophages.
###end title 29
###begin p 30
###xml 139 141 139 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M4</sub>
###xml 174 182 174 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpr</sub>
###xml 347 355 343 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Vpr</sub>
###xml 736 744 728 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;vpr</sub>
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 106 109 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 169 172 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 342 345 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 521 526 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 731 734 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Infectivity of HIV-1 variants packaging wild type or lysine-mutant Vpx proteins. Wild type HIV-1 Vpr, SIV Vpx or lysine mutant Vpx (VpxM4) proteins were packaged in HIV-1Deltavpr and infectivity of those viruses was assessed on macrophages. Viral cDNA synthesis was evaluated 24 and 48 h post-infection. (B) Infection of macrophages with HIV-1DeltaVpr GFP variants packaging wild type or mutant Vpx proteins. Cells were visualized 48 h post-infection. (C) The ability of Vpx to enhance permissivity of macrophages to HIV-1 infection requires a functional proteasome. Macrophages were treated with the proteasome inhibitors ALLN or proteasome inhibitor 1 (Prot. 1) or with DMSO as a control. Those cells were then infected with HIV-1Deltavpr variants which had packaged wild type or lysine mutant Vpx proteins. The level of viral infection (2-LTR cDNA) was determined 24 h post-infection by PCR (error bars are s.d. of 3 replicate PCRs of a single DNA sample.)
###end p 30
###begin title 31
Vpx function requires damaged DNA binding protein 1 (DDB1)
###end title 31
###begin p 32
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-LeRouzic1">[26]</xref>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Belzile1">[30]</xref>
###xml 471 473 471 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M4</sub>
###xml 476 485 476 485 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7A</bold>
###xml 476 485 476 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g007"><bold>Figure 7A</bold></xref>
###xml 641 650 641 650 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7A</bold>
###xml 641 650 641 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g007"><bold>Figure 7A</bold></xref>
###xml 1248 1257 1248 1257 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7B</bold>
###xml 1248 1257 1248 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g007"><bold>Figure 7B</bold></xref>
###xml 1257 1270 1257 1270 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, left panels</bold>
###xml 1441 1450 1441 1450 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7C</bold>
###xml 1441 1450 1441 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g007"><bold>Figure 7C</bold></xref>
###xml 1450 1469 1450 1469 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, upper right panel</bold>
###xml 1551 1560 1551 1560 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7C</bold>
###xml 1551 1560 1551 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g007"><bold>Figure 7C</bold></xref>
###xml 1560 1579 1560 1579 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, lower right panel</bold>
###xml 1912 1922 1912 1922 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Figure S3</bold>
###xml 1912 1922 1912 1922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000057.s003"><bold>(Figure S3</bold></xref>
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 294 297 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 302 307 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 397 400 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 428 431 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 514 517 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 748 751 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 878 883 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 968 973 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1025 1030 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1151 1156 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1323 1326 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1360 1363 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1509 1514 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1874 1877 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1896 1901 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recent studies have demonstrated that the ability of HIV-1 Vpr to induce cell cycle arrest requires the E3 ubiquitin ligase complex scaffolding factor, damaged DNA binding protein 1 (DDB1) [26]-[30]. Therefore, we examined whether the ability of Vpx to counteract the macrophage restriction to SIV and HIV-1 infection was DDB1-dependent. In 293T cells, endogenous DDB1 associated with a wild-type SIV Vpx protein but not with a SIV Vpx mutant lacking lysine residues (VpxM4) (Figure 7A). A specific association of SIV Vpx with DDB1 was apparent in coimmunoprecipitation experiment with either FLAG-tagged Vpx or with HA-tagged Vpx proteins (Figure 7A). If DDB1 is a functional Vpx interactor, we would predict that DDB1 silencing would only impact SIV infection of macrophages in which the restriction was expressed but not in COS cells which lack the restriction. In addition, HIV-1 Vpr did not antagonize a macrophage restriction. The activity of the restriction in HIV-1 was only revealed by the ability of Vpx to enhance HIV-1 infection of macrophages. Therefore, a prediction is that DDB1 silencing should not inhibit infection of macrophages by HIV-1. DDB1 specific siRNAs efficiently reduced DDB1 expression in COS cells and in macrophages (Figure 7B, left panels). While DDB1 silencing had no significant effect on SIV infection of COS cells (p>0.05), SIV infection was significantly impaired (p<0.005) in DDB1-depleted macrophages (Figure 7C, upper right panel). In contrast, macrophage infection by HIV-1 was not affected by DDB1 silencing (Figure 7C, lower right panel). We also used an independent strategy to deplete DDB1 in macrophages to assess its role in virus infection. Similar to the results obtained with siRNA mediated DDB1 depletion, depletion of DDB1 using DDB1-specific shRNAs also specifically impaired the susceptibility of primary macrophages to SIV infection but not HIV-1 infection (Figure S3). Therefore, DDB1 appears to be a specific Vpx cofactor in primary macrophages.
###end p 32
###begin title 33
###xml 46 49 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Inactivation of the macrophage restriction to SIV by Vpx requires DDB1.
###end title 33
###begin p 34
###xml 92 94 92 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 126 128 126 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M4</sub>
###xml 19 22 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 797 800 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 805 810 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 851 854 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 859 864 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Association of SIV Vpx with endogenous DDB1. Association of DDB1 with wild-type Vpx (VpxWT) and non-ubiquitylated Vpx (VpxM4) was evaluated in 293T cells expressing FLAG-tagged Vpx (left panels) or HA-tagged Vpx (right panels) or IRES-GFP as a control. FLAG and HA immunoprecipitates were immunoblotted with DDB1 or FLAG and HA antibodies (upper panels). Levels of endogenous DDB1 and expressed Vpx in cell lysates were confirmed by Western blotting with a DDB1 antibody and with FLAG/HA antibodies respectively (lower panels). (B) Efficiency of siRNA-mediated silencing of DDB1 expression in COS cells and in macrophages was evaluated by Western blotting with DDB1 antibody at the indicated intervals post siRNA-transfection (ScrIota-scrambled siRNA control). (C) Impact of DDB1 silencing on SIV and HIV-1 infection of COS cells and macrophages. SIV and HIV-1 infection was gauged from the quantity of viral cDNA (2-LTR) at 24, 48 and 72 h post infection (+, p>0.05; *, p<0.005) (error bars are s.d. of replicate PCRs of a single DNA sample).
###end p 34
###begin p 35
###xml 394 403 394 403 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8A</bold>
###xml 394 403 394 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g008"><bold>Figure 8A</bold></xref>
###xml 517 526 517 526 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8A</bold>
###xml 517 526 517 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g008"><bold>Figure 8A</bold></xref>
###xml 644 653 644 653 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8A</bold>
###xml 644 653 644 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g008"><bold>Figure 8A</bold></xref>
###xml 726 735 726 735 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 726 735 726 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g001"><bold>Figure 1A</bold></xref>
###xml 916 923 916 919 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;XR</sub>
###xml 1163 1172 1159 1168 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C</bold>
###xml 1163 1172 1159 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g008"><bold>Figure 8C</bold></xref>
###xml 1363 1372 1359 1368 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C</bold>
###xml 1363 1372 1359 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g008"><bold>Figure 8C</bold></xref>
###xml 1521 1530 1517 1526 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C</bold>
###xml 1521 1530 1517 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g008"><bold>Figure 8C</bold></xref>
###xml 99 104 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 144 149 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 223 228 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 295 300 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 500 505 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 610 615 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 662 665 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 678 681 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 776 779 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 808 811 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 908 911 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1269 1274 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1279 1282 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1667 1672 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1677 1680 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
We next examined whether DDB1 was required for the ability of Vpx to counteract the restriction to HIV-1 infection. Since Vpx, when packaged in HIV-1 virions, enhanced macrophage infection, we examined whether Vpx enhanced HIV-1 infection in DDB1 depleted macrophages. While packaging of Vpx in HIV-1 particles markedly increased infectivity for macrophages transfected with a scrambled siRNA (Figure 8A) silencing of DDB1 in macrophages significantly reduced (p<0.002) the ability of Vpx to enhance HIV-1 infection (Figure 8A). However, DDB1 silencing had no significant effect (p>0.05) on the infectivity of HIV-1 which had not packaged Vpx (Figure 8A). Since SIV Vpx but not SIV Vpr was essential for macrophage infection (Figure 1A), we examined whether fusion of DDB1 to SIV Vpr was sufficient to allow SIV Vpr to counteract the macrophage restriction. Packaging of Vpr alone into a Vpr and Vpx deleted SIV (SIVDeltaXR) did not permit macrophage infection. In contrast, there was a partial and significant (p<0.005) restoration of infectivity when a Vpr-DDB1 fusion was packaged relative to infectivity of virions in which the DDB1 protein was not packaged (Figure 8C). Although ubiquitylation was necessary for the ability of Vpx to counteract the restriction to HIV-1 and SIV infection of macrophages, DDB1 protein was not required for Vpx ubiquitylation (Figure 8C). Mono and poly ubiquitylated forms of Vpx were evident and apparently increased in cells in which DDB1 expression was reduced by RNA interference (Figure 8C). Collectively, these results suggest that DDB1 is required for the ability of Vpx to antagonize a restriction to infect macrophages by HIV-1 and SIV but that DDB1 is not required for Vpx ubiquitylation.
###end p 35
###begin title 36
###xml 97 102 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
DDB1 is required for the ability of Vpx to counteract the restriction to macrophage infection by HIV-1.
###end title 36
###begin p 37
###xml 57 65 57 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Vpr</sub>
###xml 90 98 86 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g005">Figure 5</xref>
###xml 374 381 367 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;XR</sub>
###xml 799 807 788 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003">Figure 3</xref>
###xml 4 7 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 52 55 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 366 369 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 426 429 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 435 438 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 553 556 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
(A) SIV Vpx (or GFP as a control) was packaged into HIV-1DeltaVpr virions as described in Figure 5. Infectivity of those viruses for DDB1-depleted macrophages (DDB1 siRNA) or control macrophages (ScrIota siRNA) were evaluated from levels of viral cDNA 24 h later (+, p>0.2; *, p<0.002). (B) DDB1 packaging partially substitutes for Vpx. A Vpx/Vpr deletion mutant of SIV (SIVDeltaXR) was co-transfected with vectors expressing SIV Vpr, SIV Vpx, DDB1 or a Vpr-DDB1 fusion. Infectivity of the resulting viruses for macrophages was evaluated from levels of SIV cDNA at 24 and 48 h post infection (*, p<0.005). (C) Impact of DDB1 silencing on Vpx ubiquitylation. 293T cells were cotransfected with DDB1 or scrambled siRNAs and with HIS-ubiquitin and HA-Vpx or IRES-GFP expression plasmids as outlined in Figure 3. Ubiquitin-conjugated proteins were nickel purified and immunoblotted for Vpx (HA). Cell lysates were directly blotted for Vpx and DDB1 proteins (lower two panels).
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 790 794 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Groschel1">[31]</xref>
###xml 795 799 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Wu1">[35]</xref>
###xml 881 885 881 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Groschel1">[31]</xref>
###xml 1316 1320 1316 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Goujon1">[17]</xref>
###xml 1419 1423 1419 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Goujon1">[17]</xref>
###xml 1561 1565 1561 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Goujon1">[17]</xref>
###xml 1825 1829 1825 1829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Goujon1">[17]</xref>
###xml 2106 2110 2106 2110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Goujon1">[17]</xref>
###xml 502 505 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 524 529 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 591 594 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 707 712 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 935 940 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1786 1789 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1798 1803 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1852 1857 <span type="species:ncbi:9606">human</span>
###xml 2141 2144 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Our study suggests that the function of Vpx is to antagonize an antiviral restriction in macrophages. Vpx exhibits similarities with the Vif protein of primate lentiviruses in that inactivation of the restriction required the proteasome/ubiquitin system. A role for the proteasome/ubiquitin system is provided by our demonstration that ubiquitylation mutants of Vpx are functionally attenuated and treatment of macrophages with proteasome disrupting agents specifically reduces their susceptibility to SIV infection but not HIV-1 infection. The inhibitory effect of proteasome inhibitors on SIV infection of primary macrophages as reported in our study appears to be at odds with studies demonstrating that HIV-1 infection of cell lines is enhanced in the presence of proteasome inhibitors [31]-[35]. The majority of these studies have involved cell lines and one of these studies [31] has suggested that proteasome inhibitors enhance HIV-1 infection by inducing G2/M cell cycle arrest thereby imparting a cellular environment that is more permissive to infection. Our study used primary macrophages and since these cells are terminally differentiated and nondividing, enhancing effects of proteasome inhibitors due to cell cycle arrest would not be manifest. A comparison of our study with the study Goujon et. al. [17] demonstrates that Vpx is essential for infection of macrophage (our study) and of dendritic cells [17]. However, there are some differences in the results obtained with Vpx mutant viruses in these two systems. In the study of Goujon et al. [17], the proteasome inhibitor MG132 marginally (1-2 fold) increased viral DNA accumulation in dendritic cells in the presence of Vpx whereas in our study, proteasome inhibitors markedly inhibited infection of macrophages by SIV but not HIV-1. Since Goujon et al. [17] reported that primary human dendritic cells were highly sensitive to the toxic effects of MG132, it is possible that differences in treatment conditions that can be employed in macrophages versus dendritic cells could account for these differences. The study of Goujon et al. [17] also showed an enhancement of SIV infection in the absence of Vpx. We did not examine the effects of proteasome inhibitors on a Vpx-deleted virus in macrophages because this variant was essentially dead in these cells.
###end p 39
###begin p 40
###xml 1839 1848 1839 1848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003">Figure 3B</xref>
###xml 1850 1861 1850 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g006">Figure 6A,B</xref>
###xml 2111 2120 2111 2120 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 2111 2120 2111 2120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g003"><bold>Figure 3A</bold></xref>
###xml 2193 2197 2193 2197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Wang1">[24]</xref>
###xml 2198 2202 2198 2202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Cadwell1">[25]</xref>
###xml 283 286 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 374 379 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 554 557 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1048 1051 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 2644 2647 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 2993 2998 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3010 3015 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3170 3175 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3245 3250 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3347 3352 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3465 3470 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 3626 3629 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Our study implicates DDB1 as a cellular cofactor of Vpx which is necessary for the ability of Vpx to counteract the macrophage restriction. This is supported by several independent experiments. DDB1 silencing in macrophages specifically impaired their susceptibility to infection by SIV and, in addition, impaired the ability of Vpx to enhance infectivity of macrophages by HIV-1. It is not possible to conclude at present whether DDB1 association accounts, in totality, for the biological activity of Vpx. DDB1 silencing led to a 5-10 fold reduction in SIV infectivity of macrophages whereas there was a 100 fold infectivity defect imparted by deletion of Vpx. However, RNA silencing failed to completely deplete DDB1 from primary macrophages and it is possible that residual DDB1 allowed some retention of Vpx activity in these macrophages. We also present evidence that DDB1 binds to ubiquitylated Vpx and that lysine mutants of Vpx which are inefficiently ubiquitylated exhibit reduced DDB1 binding and are impaired in their ability to support SIV infection of macrophages. Using a Vpx mutant lacking lysine residues, we present evidence that Vpx ubiquitylation is important for association with DDB1 and to counteract the macrophage restriction. Although we attribute loss of Vpx function to lack of ubiquitylation and loss of DDB1 binding, we cannot rule out the possibility that loss of function of the mutant protein was due to indirect effects of the mutations on protein structure. However, at the very least, the Vpx lysine mutant is packaged within virions which suggests that it is competent for interaction with the p6 domain of the Gag polyprotein. As with DDB1 silencing, the reduction in Vpx function imparted by mutation of all four lysines in Vpx caused a no more than a 10 fold defect in Vpx function (for example, see Figure 3B; Figure 6A,B). Therefore, ubiquitylation and DDB1 association may not fully account for the biological activity of Vpx in macrophages. However, polyubiquitylated forms of Vpx were still evident in cells transfected with a Vpx mutant lacking all lysine residues (Figure 3A). This suggests some degree of Vpx ubiquitination on nonlysine residues [24],[25]. Identification and mutagenesis of all ubiquitination residues on Vpx will be required before the degree to which Vpx activity depends upon ubiquitination can fully be assessed. Our study also suggests that DDB1 is not required for Vpx ubiquitylation but that Vpx ubiquitylation is necessary for association with DDB1. Therefore, the loss of function observed with the Vpx lysine mutant is likely to reflect a loss in DDB1 binding. Although SIV Vpr did not counteract the macrophage restriction, fusing it to DDB1 partially conferred this ability. This suggests that the function of Vpx may be to tether DDB1 to the reverse transcription complex upon which the restriction acts. Our study also indicates that DDB1 is required for the ability of Vpx to counter the macrophage restriction to HIV-1 infection. HIV-1 Vpr did not exhibit the ability to counter the macrophage restriction. For this reason, silencing of DDB1 did not impair susceptibility of macrophages to HIV-1 infection. However, the fact that the restriction was active against HIV-1 was revealed by the demonstration that Vpx greatly increased the permissivity of macrophages to HIV-1 infection. In this situation, silencing of DDB1 inhibited the ability of Vpx to enhance macrophage infection by HIV-1. Although Vpx is a virion protein, we do not know if DDB1 itself is packaged within virions. However, since silencing of DDB1 in the target cell inhibited SIV infection, this suggests that Vpx usurps DDB1 after infection of the target cell and likely, within the context of the reverse transcription complex.
###end p 40
###begin p 41
###xml 840 842 840 842 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 94 99 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 100 103 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 179 184 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 233 236 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 292 295 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 401 406 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 475 480 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 672 677 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 686 689 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 817 822 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 831 836 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
Our study also reveals a paradox with regards to the functional consequences of HIV-1 Vpr and HIV-2/SIV Vpx interaction with DDB1. DDB1 mediates the cell cycle arrest property of HIV-1 Vpr. DDB1 was also necessary for the ability of SIV Vpx to counteract the macrophage restriction. However, SIV Vpx, although able to interact with DDB1, does not induce cell cycle arrest. Furthermore, the ability of HIV-1 Vpr to interact with DDB1 does not appear sufficient to confer upon HIV-1 Vpr the ability to efficiently counteract the macrophage restriction. Therefore, there are likely to be different biological outcomes that are dictated by the nature of the interactions that HIV-1 Vpr and SIV Vpx forge with DDB1 and its associated E3 ubiquitin ligase complex components. Further insight into the mechanisms employed by HIV-1 Vpr and HIV-2/SIVSM Vpx to enhance macrophage infection may be revealed once the macrophage restriction itself is identified.
###end p 41
###begin title 42
Materials and Methods
###end title 42
###begin title 43
Proviral DNAs, virus stocks and infections
###end title 43
###begin p 44
###xml 34 36 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 152 154 152 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 283 285 283 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 542 545 542 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Fletcher1">[4]</xref>
###xml 711 716 711 716 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4-3</sub>
###xml 885 893 881 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000057-g002">Figure 2</xref>
###xml 970 975 962 967 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4-3</sub>
###xml 2017 2019 2005 2007 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 2070 2073 2058 2061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Fletcher1">[4]</xref>
###xml 2074 2078 2062 2066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Sharkey1">[36]</xref>
###xml 2219 2223 2207 2211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Sharkey1">[36]</xref>
###xml 2713 2717 2692 2696 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">accu</sub>
###xml 143 148 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 270 275 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 547 550 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 706 709 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 777 780 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 919 924 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 965 968 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1614 1617 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 1768 1773 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1778 1781 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 2024 2029 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2282 2285 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 2475 2478 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 2631 2634 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
The infectious molecular clone SIVSM PBj1.9 was used for the majority of experiments in this study. This clone, which is representative of the HIV-2/SIVSM group of viruses, was derived from short-term peripheral blood mononuclear cell (PBMC) cultures. Unlike many other HIV-2 and SIVSM clones, PBj1.9 has a complete set of uninterrupted accessory genes and replicates efficiently in macrophages and represents a physiologically relevant virus strain. Mutations which abrogated the translation of Vpx and Vpr genes are as described previously [4]. HIV-GFP (a gift of Paul Clapham, University of Massachusetts Medical School) contains an EGFP gene inserted between the envelope stop codon and nef within the HIV-1NL4-3 backbone. GFP expressing variants of wild type and DeltaVpx SIV contain an EGFP gene inserted between Bst 1107I sites within the viral envelope gene (as schematized on Figure 2). Wild type and DeltaVpr HIV-1 variants were studied in the context of HIV-1NL4-3. For the generation of viral stocks, 293T cells were transfected with proviral DNAs (25 microg) using a modified calcium phosphate/DNA precipitation method (Stratagene). Viruses were pseudotyped with VSV envelope glycoproteins by cotransfection of proviral DNAs with a plasmid expressing the VSV envelope glycoprotein. For encapsidation of wild type and mutant Vpx and Vpr proteins, 293T cells were cotransfected with proviral DNAs and plasmids expressing Vpx and Vpr proteins. The DNA ratio for pVSV-G, proviral clones and pIRES2-EGFP-Vpx was 1:14:1. For encapsidation of Vpr-DDB1 fusion proteins, 293T cells were co-transfected with an SIV deltaVpx/deltaVpr proviral clone, pIRES2-EGFP Vpr-fDDB1 and pVSV-G. The DNA ratio for pVSV-G, proviral clone and DDB1 expression plasmids was 1:14:1. HIV-1 and SIV stocks were normalized on the basis of reverse transcriptase activity. Viral infection efficiency was gauged from synthesis of viral cDNA products at early intervals (24 and 48 h) post-infection. PCR conditions for amplification of SIVSM and HIV-1 2-LTR cDNAs are as described previously [4],[36]. cDNA copy numbers were expressed on a per cell basis after quantitation of genomic DNA copy numbers using PCR and primers to the CCR5 gene [36]. Macrophages were initially infected with VSV-pseudotyped SIV variants harboring intact or defective Vpx genes. Viruses used in the initial infection additionally lacked an intact envelope open reading frame. Macrophages were then super-infected with SIV variants which harbored intact envelope genes. As a consequence, cDNA products generated specifically by the super-infecting virus could be identified. SIV cDNA products were amplified in two rounds of PCR with JumpStarttrade mark RedaccuTagtrade mark DNA polymerase (Sigma). First round products were amplified using forward (taacaggaacaccagcaccaaca) and reverse (catctgctttccctgacaa) primers. Second-round products were amplified using forward (taacaggaacaccagcaccaaca) and reverse (aagcataacctggcggtgcaca) primers.
###end p 44
###begin title 45
Gradient purification of virions
###end title 45
###begin p 46
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 241 242 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 415 416 407 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
Supernatants from 293T cells transfected with infectious molecular clones were cleared of cellular debris by low-speed centrifugation (1500 g, 10 min) and then filtered (0.45 microm). Virions in clarified supernatants were harvested (10,000 g, 2 h) and resuspended in serum-free medium (500 microl). Concentrated virions were applied to a 15-60% w/v continuous sucrose gradient and virions were resolved at 200,000 g for 16 h. Gradient fractions (0.5 ml) were collected and virus levels in each fraction were measured by reverse transcriptase activity. Virus particles in individual gradients were pelleted and resuspended in sample buffer and the presence of encapsidated Vpx proteins was examined by Western blotting with an alphaHA antibody.
###end p 46
###begin title 47
Macrophages and cell lines
###end title 47
###begin p 48
###xml 136 141 <span type="species:ncbi:9606">human</span>
Peripheral blood monocytes were obtained by elutriation and counter current centrifugation and maintained 2 days in DMEM containing 10% human serum and monocyte colony stimulating factor (MCSF) (RD Systems) and for a further 5 days in medium lacking MCSF prior to use in experiment. 293T, Hela and COS cells were maintained in DMEM containing 10% FBS.
###end p 48
###begin title 49
Proteasome inhibition
###end title 49
###begin p 50
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Macrophages or COS cells (8x105) in 24 well plates were directly infected with VSV-G-pseudotyped viruses (1x106 cpm RT/ml or 1 ug p24/ml) in the presence of proteasome inhibitors including Lactacystine (10 uM), ALLN (50 uM) and Proteasome inhibitor 1 (50 uM). After 3-5 h, supernatant was removed and replaced with fresh medium containing proteasome inhibitors. After 24 and 48 h post-infection total DNA was isolated using DNAzol reagent (Invitrogen) and analyzed by real-time PCR assay for 2LTR circles.
###end p 50
###begin title 51
Cell staining
###end title 51
###begin p 52
###xml 32 37 <span type="species:ncbi:9606">human</span>
For FACS analyis, COS cells and human macrophages were stained with 3.5 microM CellTracker Green CMFDA (5-chloromethylfluorescein diacetate) and 24 microM CellTracker Blue CMAC (7-amino-4-chloromethylcoumarin), respectively. For fluorescence microscopy, COS cells and macrophages were stained with 2.5 microM DiO (3,3'-dioctadecyloxacarbo cyanine perchlorate) and 12 microM DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate) respectively, according to manufacturer's instructions (Molecular Probes).
###end p 52
###begin title 53
Cell fusion
###end title 53
###begin p 54
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 157 159 157 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g.</italic>
###xml 466 467 460 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 783 787 777 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-McGinnes1">[37]</xref>
###xml 1038 1040 1032 1034 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 1047 1055 1041 1045 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Vpx</sub>
###xml 731 754 <span type="species:ncbi:11176">Newcastle disease virus</span>
Generation of macrophage homokaryons was achieved by polyethylene glycol (PEG). Briefly, labeled cells, 15x106 each group, were mixed and centrifuged at 250 g. 50% PEG-1450 was added dropwise to the pellet and cells incubated for 2 min at 37degreesC with gentle mixing. 1 ml PBS was then added dropwise to the cells over 1 min, followed by 3 ml of 2% FBS/PBS over another 2 minutes. Cells were washed 3 times with 2% FBS/PBS and plated in a 100 mm culture dish (1x107 cells/dish). COS-macrophage and COS-COS cell fusion was achieved using paramyxovirus hemagglutinin-neuraminidase (HN) protein and fusion (F) protein. Briefly, COS cells were transfected with pCAGGS-HN and pCAGGS-F expression vectors encoding HN and F proteins of Newcastle disease virus (gift of Prof. T. Morrison) [37]. Sixteen to twenty hours post-transfection, COS cells were stained, mixed with stained macrophages (ratio 1:1.5) and plated in 100 mm dishes. COS homokaryons were generated at 1:1 ratio. After overnight incubation, cells were infected with either SIVWT or SIVDeltaVpx for 24 h. Cell sorting was performed with a FACSAria flow cytometer using the FACSDiva software (Becton Dickinson). Double-stained cells were sorted. Total DNA was isolated using DNeasy Blood and Tissue Kit (Quiagen) and analyzed by real-time PCR assay for 2LTR circles.
###end p 54
###begin title 55
Plasmids
###end title 55
###begin p 56
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 528 531 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
The SIVsm Vpx and HIV-1 Vpr genes were amplified from PBj1.9 and NL4.3 proviral clones respectively, and inserted into a pIRES2-EGFP vector (BD) either with or without a N-terminal minimum HA epitope. The upstream primer for each PCR product provided a Kozak sequence. The Vpx lysine mutants (K68,77,84,85R) were generated by Quikchange XL site-directed mutagenesis (Stratagene). The DDB1 gene was amplified and subcloned from pBj-hp125 (ATCC, MBA-126) and inserted into pIRES2-EGFP as an in frame fusion with the C-terminal of SIV Vpr. A Flag epitope was added to the N-terminal of DDB1 as flanking sequences between Vpr and DDB1. As a control, a N-terminal Flag tagged DDB1 was inserted into pIRES2-EGFP.
###end p 56
###begin title 57
Analysis of Vpx ubiquitylation
###end title 57
###begin p 58
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Ward1">[38]</xref>
###xml 841 842 831 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 844 845 834 835 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
293T cells were co-transfected with HA-Vpx, HA-Vpx lysine mutants or a pIRES2-EGFP empty vector and pRGB4-6His-myc-Ubiquitin at a 1:4 ratio using lipofectamine 2000 (Invitrogen). Non-6His tagged Ubiquitin was included as a control for Ni-NTA pull-down. 36 h after transfection, the 6His-ubiquitin conjugated proteins were purified using Ni-NTA Magnetic Agarose beads (Qiagen) under native conditions [38]. Briefly, cells were lysed in detergent buffer (10 mM Tris-Hcl pH7.5, 150 mM NaCl,1% Triton X-100 and protease inhibitor cocktail) and clarified by centrifugation at 14,000 rpm for 15 min. The cell lysates were incubated with Ni-NTA beads overnight at 4degreesC in detergent buffer with 300 mM NaCl, 20 mM imidazole and 5 microM MG132. The beads were washed in lysis buffer and attached proteins were eluted in elution buffer (50 mM NaH2PO4, 375 mM NaCl, 1% Triton, 250 mM imidazole pH 8.0).
###end p 58
###begin title 59
Immunoblotting
###end title 59
###begin p 60
###xml 493 497 <span type="species:ncbi:9925">Goat</span>
Virus pellets were lysed in RIPA buffer (50 mM Tris-Hcl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% NaDoc, 0.1% SDS and protease inhibitor cocktail) lysates of transfected cells or gradient purified virions were boiled in sample buffer, resolved by SDS/PAGE and Western blotted with the following antibodies: HA-Vpx (HA, 16B12, Covance), myc-Ubiquitin (alpha-ubiquitin, P4G7, Covance; alpha-Myc 9E10, Sigma), Capsid (polyclonal, ABI), gamma-tubulin (GTU-88, Sigma), Flag-Vpx (M2, F3165, Sigma), DDB1 (Goat polyclonal antibody PC718,Calbiochem).
###end p 60
###begin title 61
RNA interference of DDB1
###end title 61
###begin p 62
The siRNA sequences for DDB1 silencing in macrophages, COS-1 or 293T cells were
###end p 62
###begin p 63
###xml 8 27 8 27 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCAAGGACCTGCTGTTTAT</named-content>
siRNA1: GCAAGGACCTGCTGTTTAT
###end p 63
###begin p 64
###xml 8 27 8 27 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCATGCCAGCATTGACTTA</named-content>
siRNA2: GCATGCCAGCATTGACTTA
###end p 64
###begin p 65
###xml 8 27 8 27 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CCTGCATCCTGGAGTATAA</named-content>
siRNA3: CCTGCATCCTGGAGTATAA
###end p 65
###begin p 66
###xml 41 60 41 60 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CAGTCGCGTTTGCGACTGG</named-content>
The Scrambled control siRNA sequence was CAGTCGCGTTTGCGACTGG
###end p 66
###begin p 67
Macrophages or COS-1 cells were transfected twice with 60 pmol each siRNA using lipofectamine 2000. 24 h after siRNA transfection, cells were infected with RT-normalized virus as indicated. The DDB1 protein knockdown levels were examined at the same time point as cDNA analysis.
###end p 67
###begin p 68
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000057-Janas1">[39]</xref>
###xml 245 248 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 252 257 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
For shRNA-mediated DDB1 silencing, macrophages are infected with a TRIP lentiviral vector [39] containing or lacking DDB1 hairpin sequences. 48 h after transduction with shRNA lentivirus vectors, macrophages were infected with VSV-g-pseudotyped SIV or HIV-1 and levels of viral cDNA synthesis was assessed after additional 48 h (96 h post lentivirus vector transduction).
###end p 68
###begin title 69
Vpx-DDB1 co-immunoprecipitation
###end title 69
###begin p 70
293T cells were transfected with Flag-Vpx, Flag-Vpx lysine mutant (VpxM4) or pIRES2-EGFP vector. 36 h after transfection, cells were harvested and lysed in Co-IP lysis buffer (100 mM NaCl, 50 mM Tris-Hcl pH 7.5, 5 mM MgCl2, 0.5% NP-40, protease inhibitor cocktail) and incubated with Protein A and Protein G beads (Invitrogen) conjugated anti-Flag M2 antibody overnight at 4degreesC. The beads were washed 4 times in a more stringent wash buffer (400 mM NaCl, 50 mM Tris-Hcl pH 7.5, 5 mM MgCl2, 0.5% NP-40, protease inhibitor cocktail). And bound proteins were boiled and eluted in 2x Laemmli's SDS-sample buffer.
###end p 70
###begin title 71
Statistical Analysis
###end title 71
###begin p 72
###xml 62 71 62 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t test. p</italic>
Where indicated, data was analyzed using an unpaired Students t test. p values of 0.05 or lower were considered significant. Statistical analysis was performed using Graph Pad Prizm 5 software.
###end p 72
###begin title 73
Supporting Information
###end title 73
###begin p 74
###xml 75 77 75 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
Susceptibility of macrophages to infection by wild type and Vpx-deleted SIVSM variants. Virus infection was gauged from the levels of late cDNA and 2-LTR cDNA products of reverse transcription at 24 and 48 h post infection.
###end p 74
###begin p 75
(0.09 MB TIF)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sub>
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 147 152 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
Differential impact of proteasome inhibition on HIV-2WT infection of macrophage and COS cells. Effects of three different proteasome inhibitors on HIV-2 infection are indicated. Viral infection (2-LTR cDNA) was gauged 24 and 48 h post infection (error bars are s.d. of 3 replicate measures of a single sample).
###end p 77
###begin p 78
(0.12 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
###xml 92 95 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 100 105 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 313 316 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 326 331 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 347 350 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 355 360 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Differential impact of shRNA-mediated DDB1 silencing on infection of primary macrophages by SIV and HIV-1. (A) DDB1 expression in primary macrophages at 72 and 96 hours post infection with a lentivirus vector expressing a DDB1 shRNA. Control cells were infected with a non shRNA expressing lentivirus vector. (B) SIV cDNA and HIV-1 cDNA levels in SIV and HIV-1 infected macrophages 96 h after transduction with lentivirus vectors expressing a DDB1 shRNA or 96 h after transduction with a vector control. Infections done in the presence of AZT were used to assess the level of carry over viral DNA contamination.
###end p 80
###begin p 81
(0.23 MB TIF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
###xml 197 220 <span type="species:ncbi:11176">Newcastle disease virus</span>
We thank A. Dauphin for research support and S. Swingler for statistical analysis and advice, B. Mellor for preparation of the figures, K. Departie for manuscript presentation, and T. Morrison for Newcastle disease virus HN and F expression plasmids and J. Skowronski for DDB1 shRNA vectors. We also wish to acknowledge the University of Massachusetts Center for AIDS Research (CFAR) and the AIDS Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health (NIH) for assay support and reagents.
###end p 83
###begin title 84
References
###end title 84
###begin article-title 85
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology.
###end article-title 85
###begin article-title 86
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
###end article-title 86
###begin article-title 87
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
###end article-title 87
###begin article-title 88
###xml 118 120 118 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 109 114 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIMSM.
###end article-title 88
###begin article-title 89
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.
###end article-title 89
###begin article-title 90
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vpr</italic>
###xml 0 28 <span type="species:ncbi:12721">Human immunodeficiency virus</span>
Human immunodeficiency virus vpr product is a virion-associated regulatory protein.
###end article-title 90
###begin article-title 91
###xml 125 128 125 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mac</sub>
###xml 52 87 <span type="species:ncbi:11709">human immunodeficiency virus type 2</span>
###xml 92 128 <span type="species:ncbi:11711">simian immunodeficiency virus SIVmac</span>
Identification of a novel retroviral gene unique to human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac.
###end article-title 91
###begin article-title 92
###xml 80 81 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 123 127 123 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cdc2</sup>
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
###end article-title 92
###begin article-title 93
###xml 82 83 82 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2+phase of the cell cycle.
###end article-title 93
###begin article-title 94
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 104 108 104 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cdc2</sup>
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.
###end article-title 94
###begin article-title 95
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vpr</italic>
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.
###end article-title 95
###begin article-title 96
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme.
###end article-title 96
###begin article-title 97
###xml 63 98 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 167 172 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate.
###end article-title 97
###begin article-title 98
###xml 45 73 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mono-nuclear phagocytes.
###end article-title 98
###begin article-title 99
###xml 19 54 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
###end article-title 99
###begin article-title 100
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells.
###end article-title 100
###begin article-title 101
###xml 6 11 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 110 115 <span type="species:ncbi:9606">human</span>
SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells.
###end article-title 101
###begin article-title 102
###xml 59 61 59 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SM</sub>
Differential association of uracil DNA glycosylase with SIVSM Vpr and Vpx proteins.
###end article-title 102
###begin article-title 103
###xml 64 67 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Sequence analysis and acute pathogenicity of molecularly cloned SIV.
###end article-title 103
###begin article-title 104
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Evidence for a newly discovered cellular anti-HIV-1 phenotype.
###end article-title 104
###begin article-title 105
###xml 27 55 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 59 64 <span type="species:ncbi:9606">human</span>
An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.
###end article-title 105
###begin article-title 106
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.
###end article-title 106
###begin article-title 107
Retroviral restriction by APOBEC proteins.
###end article-title 107
###begin article-title 108
Ubiquitination of serine, threonine, or lysine residues on the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3.
###end article-title 108
###begin article-title 109
Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase.
###end article-title 109
###begin article-title 110
###xml 0 4 <span type="species:ncbi:11676?0.7906976744186046">HIV1</span>
HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase.
###end article-title 110
###begin article-title 111
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system.
###end article-title 111
###begin article-title 112
Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle.
###end article-title 112
###begin article-title 113
###xml 32 37 <span type="species:ncbi:9606">Human</span>
DDB1 and Cul4A Are Required for Human Immunodeficiency Virus Type 1 Vpr-Induced G2 Arrest.
###end article-title 113
###begin article-title 114
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vpr-Mediated G2 Arrest Involves the DDB1-CUL4A(VPRBP) E3 Ubiquitin Ligase.
###end article-title 114
###begin article-title 115
###xml 63 91 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
###end article-title 115
###begin article-title 116
###xml 49 84 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.
###end article-title 116
###begin article-title 117
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.
###end article-title 117
###begin article-title 118
Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction.
###end article-title 118
###begin article-title 119
###xml 64 69 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
###end article-title 119
###begin article-title 120
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy.
###end article-title 120
###begin article-title 121
###xml 42 65 <span type="species:ncbi:11176">Newcastle disease virus</span>
Inhibition of receptor binding stabilizes Newcastle disease virus HN and F protein-containing complexes.
###end article-title 121
###begin article-title 122
Degradation of CFTR by the ubiquitin-proteasome pathway.
###end article-title 122
###begin article-title 123
Lentiviral delivery of RNAi in hippocampal neurons.
###end article-title 123
###begin p 124
The authors have declared that no competing interests exist.
###end p 124
###begin p 125
This study was supported by grants R01 RR11589 and R01 AI37475 from the NIH to M. Stevenson.
###end p 125

